Viking Therapeutics Shares Surge 50% On Positive Obesity Drug Data
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Viking Therapeutics' stock surged by 50% following the release of updated data from its obesity drug trials. The trial participants mostly kept their weight down after switching from a weekly injection to a daily oral medication.
In contrast, shares of competitors Eli Lilly rose, while Novo Nordisk experienced a decline. The positive results for Viking's obesity treatment have positioned the company favorably in the competitive landscape of weight management therapies.
Viking TherapeuticsEli LillyNovo Nordisk
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — Viking shares surge on updated obesity drug data
SupportCorroborates it
“Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.”
Yahoo Finance — Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.